The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Subscribe To Our Newsletter & Stay Updated
